- Home
- SJT vs FENC Comparison
SJT vs FENC Comparison
Compare SJT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- FENC
- Stock Information
- Founded
- SJT 1980
- FENC 1996
- Country
- SJT United States
- FENC United States
- Employees
- SJT N/A
- FENC N/A
- Industry
- SJT Oil & Gas Production
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJT Energy
- FENC Health Care
- Exchange
- SJT Nasdaq
- FENC Nasdaq
- Market Cap
- SJT 269.4M
- FENC 225.4M
- IPO Year
- SJT N/A
- FENC 2001
- Fundamental
- Price
- SJT $5.78
- FENC $8.76
- Analyst Decision
- SJT
- FENC Strong Buy
- Analyst Count
- SJT 0
- FENC 2
- Target Price
- SJT N/A
- FENC $13.50
- AVG Volume (30 Days)
- SJT 198.3K
- FENC 56.4K
- Earning Date
- SJT 08-13-2025
- FENC 11-06-2025
- Dividend Yield
- SJT N/A
- FENC N/A
- EPS Growth
- SJT N/A
- FENC N/A
- EPS
- SJT N/A
- FENC N/A
- Revenue
- SJT $42,635.00
- FENC $33,302,000.00
- Revenue This Year
- SJT N/A
- FENC $0.96
- Revenue Next Year
- SJT N/A
- FENC $51.71
- P/E Ratio
- SJT N/A
- FENC N/A
- Revenue Growth
- SJT N/A
- FENC N/A
- 52 Week Low
- SJT $3.27
- FENC $3.96
- 52 Week High
- SJT $7.22
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- SJT 47.52
- FENC 50.16
- Support Level
- SJT $5.73
- FENC $8.96
- Resistance Level
- SJT $5.91
- FENC $9.23
- Average True Range (ATR)
- SJT 0.13
- FENC 0.27
- MACD
- SJT 0.01
- FENC 0.00
- Stochastic Oscillator
- SJT 26.47
- FENC 34.57
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.